Treatment with pirfenidone for two years decreases fibrosis, cytokine levels and enhances CB2 gene expression in patients with chronic hepatitis C
Lucia Flores-Contreras,Ana Sandoval-Rodriguez,Mayra Mena-Enriquez,Silvia Lucano-Landeros,Inmaculada Arellano-Olivera,Arnulfo Álvarez-Álvarez,M Guadalupe Sanchez-Parada,Juan Armendáriz-Borunda +7 more
Reads0
Chats0
TLDR
Pirfenidone for two years benefits CHC patients and improves inflammation, fibrosis and steatosis in higher number of patients as previously shown for 12-months treatment with PFD.Abstract:
The aim of this study was to assess whether two-years treatment with Pirfenidone influences necroinflammation, fibrosis and steatosis, serum levels of TGF-β1, IL-6, TNF-α and CB1 and CB2 gene expression, in patients with chronic hepatitis C (CHC). Twenty-eight patients out of 34 with CHC virus infection were enrolled in the study and received Pirfenidone (1200 mg/day) for 24 months. Six patients dropped out after 12 months of PFD. Liver biopsies and serum samples were obtained at the beginning and end of treatment. Modified HAI was calculated. CB1 and CB2 gene expression was correlated with fibrosis progression alongside with necroinflammation and steatosis. TGF-β1, IL-6, TNF-α and liver transaminases were measured in serum at two-months intervals. HCV genotype and viral load were also assessed. Quality of life was evaluated by SF36 questionnaires and the prognosis of disease was assessed with Child-Pugh score. The Wilcoxon test matched-pair signed ranks were used to analyze the outcomes. Intention to treat analyses were performed for biochemistry and clinical parameters. At the end of treatment, necroinflammation grading was reduced in an average of 3.2 points in 82% of patients (p < 0.05) and Ishak’s fibrosis stage decreased 2-points average in 67% of patients (p < 0.05). Steatosis decreased in 61% of patients. IL-6 and TGF-β1 serum levels decreased significantly in 93% and 67% of patients (p < 0.05), respectively, while TNF-α diminished in 47% of patients. ALT and AST tended to normalize in 81% of patients; CB2 mRNA levels increased in 86% and CB1 expression diminished in 29% of patients. Both, quality of life and Child-Pugh score improvements were reported in all patients. Pirfenidone for two years benefits CHC patients and improves inflammation, fibrosis and steatosis in higher number of patients as previously shown for 12-months treatment with PFD. Additionally, PFD improved TGFβ1 and IL-6 levels and diminished liver expression of anti-fibrogenic receptor CB2. ClinicalTrials.gov identifier: NCT02161952
. Protocol Registration Date: 06/11/2014.read more
Citations
More filters
Journal ArticleDOI
Kinase inhibition in autoimmunity and inflammation
TL;DR: The activity of kinases that regulate production of inflammatory mediators and the recent advances in developing inhibitors to target such kinases are discussed.
Journal ArticleDOI
Management Strategies for Liver Fibrosis
TL;DR: The aim of this review is to identify the therapeutic options available for the treatment of the liver fibrosis, enabling the prevention of progression when is detected in time.
Journal ArticleDOI
Oxidative stress, a trigger of hepatitis C and B virus-induced liver carcinogenesis
Alexander V. Ivanov,Vladimir T. Valuev-Elliston,Daria A. Tyurina,Olga N. Ivanova,Sergey N. Kochetkov,Birke Bartosch,Maria G. Isaguliants +6 more
TL;DR: This review summarizes current knowledge on oxidative stress and oxidative stress responses induced by human hepatitis B and C viruses and focuses on the molecular mechanisms by which these viruses activate cellular enzymes/systems that generate or scavenge reactive oxygen species (ROS) and control cellular redox homeostasis.
Journal ArticleDOI
Reversal of liver fibrosis: From fiction to reality.
TL;DR: The current developments demonstrate that reversal of liver fibrosis is turning from fiction to reality, particularly in patients with non-alcoholic steatohepatitis.
Journal ArticleDOI
A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes.
TL;DR: There is increasing evidence that ROS, inflammation and fibrosis promote each other and are part of a vicious connection leading to development and progression of CVD and kidney disease in diabetes.
References
More filters
Journal ArticleDOI
Analysis of relative gene expression data using real-time quantitative pcr and the 2(-delta delta c(t)) method
TL;DR: The 2-Delta Delta C(T) method as mentioned in this paper was proposed to analyze the relative changes in gene expression from real-time quantitative PCR experiments, and it has been shown to be useful in the analysis of realtime, quantitative PCR data.
Journal ArticleDOI
Histological grading and staging of chronic hepatitis.
Kamal G. Ishak,Amelia Baptista,Leonardo Bianchi,Francesco Callea,Jan De Groote,Fred Gudat,Helmut Denk,Valeer Desmet,Gerhard Korb,R. N. M. Macsween,M. James Phillips,Bernard G. Portmann,H. Poulsen,Peter J. Scheuer,Martin Schmid,Heribert Thaler +15 more
TL;DR: This research presents a meta-analysis of Anatomia e Istologia Patologica, a large quantity of which has never before been published in a peer-reviewed journal, which aims to provide real-time information about the immune system’s response to disease.
Journal ArticleDOI
A model to predict survival in patients with end‐stage liver disease
Patrick S. Kamath,Russell H. Wiesner,Michael Malinchoc,Walter K. Kremers,Terry M. Therneau,Catherine L. Kosberg,Gennaro D'Amico,E. Rolland Dickson,M.B.A. W. Ray Kim M.D. +8 more
TL;DR: The MELD scale is a reliable measure of mortality risk in patients with end‐stage liver disease and suitable for use as a disease severity index to determine organ allocation priorities in patient groups with a broader range of disease severity and etiology.
Journal ArticleDOI
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more
TL;DR: Pirfenidone, as compared with placebo, reduced disease progression, as reflected by lung function, exercise tolerance, and progression-free survival, in patients with idiopathic pulmonary fibrosis.
Journal ArticleDOI
Liver fibrosis – from bench to bedside
TL;DR: Current knowledge about the nature and prognosis of fibrosis in different forms of chronic liver disease with recent advances in elucidating its pathophysiology form the basis for rational treatment of hepatic fibrosis, which are summarized.
Related Papers (5)
Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial
Brent A. Neuschwander-Tetri,Rohit Loomba,Arun J. Sanyal,Joel E. Lavine,Mark L. Van Natta,Manal F. Abdelmalek,Naga Chalasani,Srinivasan Dasarathy,Anna Mae Diehl,Bilal Hameed,Kris V. Kowdley,Arthur J. McCullough,Norah A. Terrault,Jeanne M. Clark,James Tonascia,Elizabeth M. Brunt,David E. Kleiner,Edward Doo +17 more
Elafibranor, an Agonist of the Peroxisome Proliferator−Activated Receptor−α and −δ, Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening
Vlad Ratziu,Vlad Ratziu,Stephen A. Harrison,Sven Francque,Pierre Bedossa,Philippe Lehert,Philippe Lehert,Lawrence Serfaty,Manuel Romero-Gómez,Jérôme Boursier,Manal F. Abdelmalek,Steve Caldwell,Joost P.H. Drenth,Quentin M. Anstee,Dean W. Hum,Rémy Hanf,A. Roudot,S. Megnien,Bart Staels,Arun J. Sanyal,Philippe Mathurin,J. Gournay,Eric Nguyen-Khac,V. de Ledinghen,Dominique Larrey,A. Tran,M. Bourliere,M. Maynard-Muet,Tarik Asselah,Jean Henrion,Frederik Nevens,David Cassiman,Albert Geerts,Christophe Moreno,Ulrich Beuers,Peter R. Galle,Ulrich Spengler,Elisabetta Bugianesi,Antonio Craxì,Mario Angelico,Silvia Fargion,M. Voiculescu,Liana Gheorghe,L. Preotescu,Juan Caballería,Raúl J. Andrade,Javier Crespo,J. L. Callera,Aftab Ala,Guruprasad P. Aithal,G. Abouda,Velimir A. Luketic,M. A. Huang,Stuart C. Gordon,Paul J. Pockros,Fred Poordad,N. Shores,M. W. Moehlen,Kiran Bambha,V. Clark,Sanjaya K. Satapathy,S. Parekh,R. K. Reddy,Muhammad Y. Sheikh,Gyongyi Szabo,John M. Vierling,T. Foster,Guillermo E. Umpierrez,C. Chang,Terry Box,J. Gallegos-Orozco +70 more
Pioglitazone, Vitamin E, or Placebo for Nonalcoholic Steatohepatitis
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis
Talmadge E. King,Williamson Z. Bradford,Socorro Castro-Bernardini,Elizabeth A. Fagan,Ian Glaspole,Marilyn K. Glassberg,Eduard Gorina,Peter Hopkins,David Kardatzke,Lisa Lancaster,David J. Lederer,Steven D. Nathan,Carlos Alberto de Castro Pereira,Steven A. Sahn,Robert Sussman,Jeffrey J. Swigris,Paul W. Noble +16 more